Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2014 · 10-Q
Revenue$9.75M$9.75M+37.7% vs Q2 2013 Net Income$722.57K$722.57KN/M vs Q2 2013 EPS Diluted$0.04$0.04N/M vs Q2 2013 Operating Income$1,215,609N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$817,337+620.3% Margins · derivedOperating margin12.5%+28.6 pt vs Q2 2013
Net margin7.4%+16.4 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 8, 2014 · 39 d after period end